login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Mixed evidence on use of radiofrequency catheter ablation for AF


Monday, 13 Jul 2009 13:24
Carolyn Clancy
Carolyn Clancy


Little is known about the long-term benefits catheter ablation for atrial fibrillation and the best methods and circumstances for applying it, according to a new report funded by the US Department of Health & Human Services’s (HHS) Agency for Healthcare Research and Quality (AHRQ).


The report examines the use of radiofrequency catheter ablation to treat AF. The new comparative effectiveness report found that the procedure has been shown to provide benefits in maintaining normal heart rhythm over short periods of time (up to one year) but found little evidence indicating whether the procedure reduces the chance that patients will experience atrial fibrillation over the long term.


The report, which compared radiofrequency ablation to medication-based therapy, also found that the effect of the procedure on stroke, a major risk for patients with atrial fibrillation, is unknown.
"Radiofrequency holds promise for treating atrial fibrillation, but it is clear that more research is needed to demonstrate its potential long-term benefits," said AHRQ director Carolyn M Clancy. "This report crystallises the questions that researchers need to ask going forward."


The report calls for more research on the effect of catheter ablation on quality of life. In particular, more research is needed for groups of patients for whom the research is especially lacking, such as women, the elderly, and patients who have other conditions such as heart failure or high blood pressure.


Earlier this year, HHS’ FDA approved the first two ablation catheters indicated for use in treating atrial fibrillation, in the US. However, physicians often use other catheters that have not been approved by the FDA for atrial fibrillation. The FDA also found that there is no conclusive evidence that people whose symptoms are reduced with ablation are less likely to have a stroke. Therefore, the FDA explicitly endorsed existing clinical guidelines that recommend that patients at risk for stroke continue to take preventive blood-thinning medications after radiofrequency catheter ablation.


As a condition of catheter approvals, the FDA mandated that the catheters’ manufacturer must conduct two post approval studies (PAS) to collect long term safety data. The mandated studies apply only to FDA-approved catheters, and not to devices used off-label in clinical practice. The first PAS is a post approval registry, which will collect safety (adverse event) data and operator experience information through seven days post-treatment with the approved ablation catheters. The study will also collect data on long-term safety data, such as death, stroke, myocardial infarction, clinically manifested pulmonary vein stenosis, etc., at five years post-treatment. The second PAS is a subgroup analysis from an ongoing larger study that will look at the incidence of stroke, and compare the three-year incidence of stroke between patients treated with the approved ablation catheters versus patients treated with medication. This study will analyse total mortality, serious bleeding and cardiac arrest.


Also, last week, the FDA approved a new medication, dronedarone, for treatment of atrial fibrillation.


Information, including the new report, can be found at www.effectivehealthcare.ahrq.gov.




Add New Comment

Most popular


Benefit of anticoagulation in AF patients with a low risk of stroke questioned
Thursday, 18 Jun 2015
The results from a retrospective study, based on a large dataset (over 140,000 patients), have cast doubt on the benefit of routine oral anticoagulants for patients with atrial fibrillation and low ... Benefit of anticoagulation in AF patients with a low risk of stroke questioned

New stem cell delivery method shows promise for treating end stage heart failure
Monday, 27 Jul 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus infusion affects end stage heart failure patients is showing promising results. New stem cell delivery method shows promise for treating end stage heart failure

Friday, 24 Jul 2015
Key topics from the hot line sessions of ESC 2015 include atrial fibrillation, pacing, acute myocardial infarction, heart failure, hypertension, diabetes mellitus, pharmacology and coronary artery ... ESC announces hot line sessions highlights

Features


Highlights EHRA EUROPACE-CARDIOSTIM 2015: Interview with Michael Glikson
Thursday, 16 Jul 2015
Michael Glikson (director of Davidai Arrhythmia Center, Heart Center, Sheba Medical Center, Tel Hashomer, Israel), vice-chairperson scientific programme for EHRA EUROPACE-CARDIOSTIM 2015, talks to C... Highlights EHRA EUROPACE-CARDIOSTIM 2015: Interview with Michael Glikson

Mechanical transvenous lead extraction vs. laser lead extraction
Tuesday, 30 Jun 2015
Maria Grazia Bongiorni (Pisa, Italy) compares mechanical transvenous lead extraction vs. laser lead extraction approaches with supporting evidence from key randomised controlled trials in the field. Mechanical transvenous lead extraction vs. laser lead extraction

Profiles


Cecilia Linde
Monday, 22 Jun 2015
Cecilia Linde speaks to Cardiac Rhythm News about her work on a research platform for new onset ... Cecilia Linde

Michael Gold
Wednesday, 03 Jun 2015
William Gold spoke to Cardiac Rhythm News about his involvement in various clinical trials, his ... Michael Gold

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions